Agenus Inc. Reports 34.5% Revenue Growth and Operating Income Turnaround in Q2 2026

Agenus Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenues of $34.5 million for the quarter, a 34.5% increase from $25.7 million in the same period last year. This growth was primarily driven by a rise in non-cash royalty revenue related to the sale of future royalties, which increased to $28.1 million from $24.8 million year-over-year. Pre-commercial product revenue from its BOT/BAL immunotherapy program also contributed, amounting to $6.4 million, compared to no revenue in the prior year. For the first half of 2026, total revenues reached $68.3 million, up from $49.8 million in the first half of 2025.

The company reported an operating income of $11.3 million for the second quarter, a notable turnaround from an operating loss of $16.7 million in the same quarter of 2025. For the first half of 2026, Agenus achieved an operating income of $26.3 million, compared to an operating loss of $30.0 million in the prior year. The improvement in profitability was attributed to a significant reduction in operating expenses, which fell by 45% to $23.2 million in the second quarter, driven by decreased research and development costs following the sale of its manufacturing operations to Zydus Lifesciences.

Agenus has also made strategic moves to enhance its operational capabilities. In January 2026, the company completed the sale of its manufacturing facilities to Zydus for $91 million, which included a $40.4 million gain recognized in the first half of 2026. This transaction not only strengthened the company's liquidity but also allowed it to focus on its core immunotherapy programs. Additionally, Agenus announced a planned registrational Phase 3 trial, named ROBBIN, for its BOT/BAL treatment in high-risk Stage II and III microsatellite-stable colon cancer, further solidifying its commitment to advancing its clinical pipeline.

As of June 30, 2026, Agenus reported cash and cash equivalents of $18.7 million, a significant increase from $3.0 million at the end of 2025. The company also closed a private placement on July 15, 2026, raising approximately $85 million, with potential additional proceeds of up to $255 million from warrants. Despite these positive developments, Agenus acknowledged ongoing challenges, including an accumulated deficit of $2.1 billion and the need for further capital to support its commercialization strategies. The company is actively pursuing additional financing options and strategic partnerships to ensure its long-term viability and growth.